Neohepatect (Human Hepatitis B Immunoglobulin)

Human Hepatitis B Immunoglobulin, the active ingredient in Neohepatect, is an Immunoglobulin (HBIG) presented as an injectable solution for intravenous use. It provides passive immunity to prevent hepatitis B infection after exposure and is used for post‑exposure prophylaxis and transplant‑related prevention. GNH USA supplies Neohepatect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Neohepatect, a hepatitis B immunoglobulin, acts on the viral infection pathway to provide passive immunity. - Post‑exposure prophylaxis after known or suspected hepatitis B exposure: prevents establishment of infection. - Prevention of hepatitis B transmission to newborns of HBsAg‑positive mothers: reduces risk of vertical transmission. - Prevention of hepatitis B recurrence after liver transplantation: maintains protective anti‑HBs titres.

Neohepatect may cause adverse reactions following intravenous administration.

Common Side Effects: - Fever: transient elevation of body temperature after infusion. - Chills: shaking sensations often accompanying fever. - Headache: mild to moderate discomfort. - Injection site reaction: redness, swelling or pain at the infusion site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Serum sickness-like reaction: fever, rash, arthralgia occurring days after exposure. - Renal dysfunction: impaired kidney function observed in rare cases.

Before using Neohepatect, consider the following precautions. - Screen for HBV immunity: assess anti‑HBs status prior to administration. - Monitor for allergic reactions: observe patient during and after infusion. - Use caution in immunocompromised patients: response may be altered. - Avoid concurrent live vaccines: may interfere with immune response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neohepatect may interact with other agents as follows.

Major Interactions (Avoid): - Concurrent administration of blood products containing anti‑HBs: may reduce efficacy. - Use with other hepatitis B immunoglobulin products: risk of antibody overload.

Moderate Interactions (Monitor Closely): - Hepatitis B vaccine: may interfere with antibody titres. - Immunosuppressants: may affect the protective response. - Nephrotoxic drugs: monitor renal function during combined therapy.